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Abstract
World Malaria Day 2015 highlighted the progress made in the development of new methods of 
prevention (vaccines and insecticides) and treatment (single dose drugs) of the disease. However, 
increasing drug and insecticide resistance threatens the successes made with existing methods. 
Insecticide resistance has decreased the efficacy of the most commonly used insecticide class of 
pyrethroids. This decreased efficacy has increased mosquito survival, which is a prelude to rising 
incidence of malaria and fatalities. Despite intensive research efforts, new insecticides will not 
reach the market for at least 5 years. Elimination of malaria is not possible without effective 
mosquito control. Therefore, to combat the threat of resistance, key stakeholders need to rapidly 
embrace a multifaceted approach including a reduction in the cost of bringing new resistance 
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management methods to market and the streamlining of associated development, policy, and 
implementation pathways to counter this looming public health catastrophe.
Introduction
In 1999, White and colleagues1 reported the escalating drug resistance in malaria parasites 
and the risks associated with the introduction of new malaria treatments as monotherapies. 
This report was one of the first steps leading to the recommendation by WHO of artemisinin 
combination therapy as the front-line drug treatment in 2001.2 These measures to minimise 
treatment failure, coupled with a massive scale-up in preventing transmission by targeting 
the mosquito vector with insecticides, have resulted in large reductions in malaria mortality 
in sub-Saharan Africa in the 21st century,3 a success highlighted on World Malaria Day 
2015. The long-term goal of malaria eradication is not possible without a focused 
multifaceted approach that combines treatment and prevention. No drug campaign or future 
vaccine roll-out will succeed without effective vector control.
The necessity of effective drugs for malaria treatment is widely accepted, and reports of 
suboptimum performance of the combination treatment of artemisinins have elicited a 
serious international response to curtail the spread of the resistant parasite.4 Malaria 
prevention relies mainly on one chemical class of insecticides, the pyrethroids; insecticide 
resistance is decreasing the efficacy of this treatment. However, the spread of insecticide 
resistance is insidious. Whereas health workers and patients recognise a failing treatment 
immediately, it is not as obvious when mosquitoes fail to respond to insecticides. Extensive 
insecticide resistance is needed before the effect on mosquito survival becomes apparent, 
and the number of cases of malaria and deaths increase.
Malaria prevention in Africa relies almost entirely on the use of insecticides in the domestic 
environment in the form of longlasting insecticide-treated bednets or indoor residual 
spraying. Use of longlasting insecticide-treated bednets reduced under-5 child mortality by 
more than 20% in both large-scale trials and under routine conditions.5,6 The distribution of 
longlasting insecticide-treated bednets has been rapidly scaled up since 2000 with an 
estimated 54% of African households at risk now possessing at least one net, although 
coverage and usage are uneven (figure 1). In 2008, Roll Back Malaria, via its Global Malaria 
Action Plan, set the target of universal population coverage for all people at risk of malaria.7 
National scale indoor residual spraying began in 1946 and was the main prevention strategy 
of the malaria elimination efforts of the 1960s. With the demise of this effort, most indoor 
residual spraying programmes stopped in sub-Saharan Africa but many continued in Asia. 
Largely spearheaded by the US President’s Malaria Initiative, indoor residual spraying has 
been reintroduced in many African countries. By 2013, 55 million people per year (about 
7% of those at risk from malaria) were protected by indoor residual spraying through this 
programme in Africa.3
Increased coverage with these preventive measures has achieved striking results with the 
estimated malaria burden halving across Africa since 2000. However, the decision to scale 
up vector control was not accompanied by plans to ensure the sustainability of these 
insecticide-based methods. Pyrethroids are the only class of insecticide recommended by 
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WHO for use on longlasting insecticide-treated bednets. When the President’s Malaria 
Initiative launched in 2005, all indoor residual spraying programmes were also using this 
insecticide class and in 2013, nearly two-thirds of indoor residual spraying programmes 
worldwide continued to rely on pyrethroids. Thus, for more than a decade, mosquito vectors 
of malaria have been targeted with a monotherapy. Inevitably, resistance has been selected, 
and in some parts of Africa pyrethroids no longer kill mosquitoes. With no new insecticide 
class to replace the pyrethroids expected for a decade, the threat of resistance derailing 
malaria control has become an issue of urgency that can no longer be ignored without 
risking a global public health catastrophe.
Current situation
As malaria vector control has escalated across Africa, so too have the number of reports of 
pyrethroid resistance in both major vector groups, Anopheles gambiae sensu lato and 
Anopheles funestus (figure 2), and it is rare to find sites in Africa where one or both these 
vectors do not show some resistance to pyrethroids.
Pyrethroid resistance was first detected in the African malaria vectors in Sudan in the 1970s 
and later in west Africa in the early 1990s8,9 and was probably selected for by exposure of 
mosquitoes to pyrethroids used to protect agricultural crops against insect damage. This 
resistance was caused by a target site mutation kdr (knockdown resistance), which spread 
rapidly across Africa. However, the level of resistance conferred by this mutation alone is 
low, and this led to complacency with the resistance having little or no operational effect on 
the efficacy of longlasting insecticide-treated bednets.10,11 Now, more potent resistance 
mechanisms have evolved, which have resulted in longlasting insecticide-treated bednets and 
indoor residual spraying pyrethroid formulations that no longer kill mosquitoes in different 
settings. These resistant mosquitoes can survive up to 1000 times the concentration of 
insecticide that kills susceptible mosquitoes, and investigators are increasingly noting blood-
fed mosquitoes inside longlasting insecticide-treated bednets or resting on newly sprayed 
walls.12–15
The study of the direct effect of insecticide resistance on malaria transmission is highly 
complex. A systematic review16 of experimental hut studies assessing long-lasting 
insecticide-treated bednets concluded that although some forms of pyrethroid resistance 
were clearly affecting entomological indicators, such as blood feeding and survival, the 
quality of the data, variability of experimental design, and inconsistency in methods of 
resistance measurement made it impossible to assess the effect on malaria transmission. 
Programmes of indoor residual spraying that have responded to pyrethroid resistance by 
switching to alternative insecticides have shown a substantial fall in cases of malaria, 
providing the most compelling evidence that pyrethroid resistance is already resulting in 
increased malaria deaths in Africa.
What can be done?
In 2012, WHO published the Global Plan for Insecticide Resistance Management in malaria 
vectors.17 This report raised awareness of the threats of resistance and put in place a high 
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level framework to manage it. This plan will soon be supplemented by guidelines for 
countries to develop their own resistance management plans. However, major operational 
challenges to implementing many of the recommendations exist. With only one insecticide 
class available for longlasting insecticide-treated bednets, and Roll Back Malaria advocating 
universal longlasting insecticide-treated bednet coverage, what should countries do when 
they detect resistance to this insecticide class? Do they continue to scale up coverage, 
exerting further selection pressure on the mosquito population? What level does resistance 
have to reach before the insecticide becomes completely ineffective? Would greater returns 
on investment be obtained by concentrating on the barrier protection provided by more 
durable nets? A proactive initiative from the global health community is needed to devise 
practical guidance on how to respond to pyrethroid resistance. This effort needs to be 
underpinned by solid evidence, which is urgently needed to guide countries currently relying 
on increased coverage with longlasting insecticide-treated bednets to reduce their malaria 
burden.
Advice on when to introduce alternative strategies to maintain control is crucial. Industry is 
starting to innovate with products designed to combat resistance, such as bi-treated nets and 
longer lasting non-pyrethroid indoor residual spray formulations with single insecticides or 
as mixtures. Countries need to know under what resistance scenarios innovative products, 
including those designed to overcome specific resistance mechanisms, might provide better 
protection than conventional longlasting insecticide-treated bednets.
Alternative chemical entities for use in indoor residual spraying are available, although 
resistance to these is increasing too. Here the guidance from WHO is clear, but so far, very 
few African countries have well developed resistance management plans for indoor residual 
spraying,18,19 and for some countries, faced with resistance to all available chemistries, the 
advice is of theoretical rather than practical relevance. In any case, all insecticide resistance 
management strategies need the introduction of methods that are more expensive than 
current interventions. In theory, short-term increases in expenditure are rewarded by long-
term gains because the effectiveness of available quality methods is prolonged and the 
expense (in economic and disease burden terms) of control failure is averted. But how do 
control programmes, and donors operating on fixed or declining budgets balance the need to 
maintain coverage levels with the demands to change to more costly insecticide classes to 
preserve insecticide susceptibility?
Ultimately, the successful implementation of the WHO global plan requires the development 
and operational deployment of new insecticides. The Product Development Partnership 
IVCC20 are working with industry to develop novel public health-specific insecticides and 
bring these to market. With several of these urgently needed products in the pipeline, a 
concerted effort has to be made to streamline the developmental, regulatory, and WHO 
recommendation pathways. Without such steps, entry of these new insecticides to the market 
is expected to be at least 5 years away. Furthermore, in view of the time, cost, and difficulty 
associated with operational implementation of new public health insecticides, these new 
products should never be introduced as large-scale monotherapies for malaria prevention. As 
with drugs and antibiotics, it is essential that insecticide resistance management starts before 
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resistance is selected, ideally before the product is released into the market, and not as a 
reaction to rapidly increasing resistance or increased disease transmission.
It is time to take a more urgent and proactive approach to insecticide resistance. Most 
immediately, all relevant partners need to stop simply noting the growing resistance trend 
and work together to ensure that the ability to prevent malaria is maintained. Countries 
should be helped to develop rational malaria prevention strategies that will prolong the 
efficacy of current vector control methods, and ensure that these are adequately supported by 
the major donors. We cannot be paralysed by the absence of data and having to work under 
resource-constrained conditions. Learning on the job will be crucial to refine 
recommendations and provide an evidence base for new insecticides, interventions, and 
resistance management strategies.
In parallel, the global malaria community need to accelerate the development of new 
insecticides and other non-insecticide-based vector control methods, and their pathway to 
market. In doing so, researchers need to learn from the lessons from the past and introduce 
new insecticides in a format that will ensure that they are not rapidly compromised by 
resistance. To realise these ambitions, and to ensure that vector control continues to save 
lives, a goals-driven alliance is needed of all key stakeholders (research and implementation 
funders, government organisations, non-government organisations, academia, industry and 
other innovators, and WHO), each committed to playing its part. Without this approach, 
much of the hard won progress in reducing malaria transmission will be lost.
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Figure 1: The change in longlasting pyrethroid treated bednet coverage in Africa, 2000–12
ITN=insecticide-treated bednets. Pf=Plasmodium falciparum.
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Figure 2: Reports of pyrethroid resistance in African malaria vectors, for (A) 1995–2000 and (B) 
2008–14
Red dots show resistant populations according to WHO’s definition of less than 90% 
mortality after exposure to a discriminating dose; green dots show susceptible populations. 
Base map shows malaria endemicity. Reproduced from IR Mapper, by permission of IR 
Mapper, October, 2014.
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